-transparent.png){kind=logo}
Sixteen patients with multiple myeloma refractory to alkylating agents were treated with vincristine 0.25 mg/m2 i.v. on days 1 to 4 and prednisone 1 gm/m2 on days 1 and 3. Chemotherapy was repeated every 2 weeks. Of 15 evaluable patients, five achieved a partial response and four stable disease. Three patients with partial response and three with stable disease relapsed at 6, 7, and 16 and at 5, 9, and 10 months, respectively. The median survival for all patients was 10 1/2 months and it ranged from 1 to 21 + months. The median survival in responders was not reached at 13 months. Onset of antitumor effect was observed within the first 2 weeks. Symptomatic relief of bone pain was noted within 48 hours in responders and nonresponders. Improvement in bone marrow cellularity and decrease in plasma cell infiltration was documented in more than one-half of the responders. Tolerance to the treatment was good. No hematologic or other significant toxicity was observed.
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
May 1984,
The New England journal of medicine,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
September 1983,
Cancer,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
April 1974,
Cancer,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
January 1975,
Archives of internal medicine,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
October 1975,
Blood,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
January 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
January 1972,
The West Virginia medical journal,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
June 1987,
Revue du rhumatisme et des maladies osteo-articulaires,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
March 2024,
Haematologica,
G A Gomez, and
T Han, and
H Ozer, and
E S Henderson
December 2006,
Zhongguo shi yan xue ye xue za zhi,
